ClinicalTrials.gg
CompletedNCT01334957Updated Feb 28, 2024Results posted

Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

A Phase 4 interventional study of Intravenous ibuprofen in Pain, sponsored by Cumberland Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Cumberland Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
13th of 86
300 · median 100
Started
2011
with 6 others
Phase 4
30 of 86
3 open now
Registered
21st of 86
by date
Lead sponsor
6 of 86
Cumberland Pharmaceuticals

Among the 86 studies testing ibuprofen in Pain, this one is the 13th largest by enrollment, is one of 7 that started in 2011, is one of 30 in phase 4, and was the 21st registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the safety of a single dose of intravenous ibuprofen administered over 5-10 minutes for the preemptive treatment of postoperative pain.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for surgery with anticipated need for postoperative analgesia

Exclusion criteria

Exclusion Criteria:

  1. Patients with inadequate IV access
  2. Patients \<18 years of age
  3. History or allergy or to any component of intravenous ibuprofen, aspirin (or aspirin related products) or non-steroidal anti-inflammatory drug (NSAIDs)
  4. Active hemorrhage or bleeding
  5. Pregnant or nursing
  6. Patients in the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery
  7. Inability to understand the requirements of the study, be willing to provide written (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]), and agree to abide by the study restrictions
  8. Refusal to provide written authorization for use and disclosure of protected health information
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Intravenous ibuprofen

    Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.

    Drug: Intravenous ibuprofen

Interventions

  • 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes

    Also known as: Caldolor

06

What researchers measure

Primary outcomes

  1. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.

    The incidence of treatment-emergent serious adverse events occurring in the six hours following administration of the first dose of intravenous ibuprofen

    Time frame: 6 hours

  2. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.

    The incidence of treatment-emergent adverse events occurring in the six hours following administration of the first dose of intravenous ibuprofen

    Time frame: 6 hours

Secondary outcomes

  1. To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.

    The incidence of treatment-emergent serious adverse events occurring in the six hours following administration of the last dose of intravenous ibuprofen

    Time frame: 6 hours

  2. To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.

    The incidence of treatment-emergent adverse events occurring in the six hours following administration of the last dose of intravenous ibuprofen

    Time frame: 6 hours

  3. To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.

    Visual Analog Scale (VAS) assessments following surgery. The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between o and 100.

    Time frame: 6 hours

07

Results

Posted Jun 23, 2014

Participant flow

Adult hospitalized patients undergoing surgery

Participant flow — Overall Study
MilestoneIntravenous Ibuprofen
Started300
Received single dose252
Received multiple doses48
Completed300
Not completed0

Outcome measures

PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.

The incidence of treatment-emergent serious adverse events occurring in the six hours following administration of the first dose of intravenous ibuprofen

Time frame:
6 hours
Reported as:
Number · Number of Serious Adverse Events
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.
Number of Serious Adverse EventsIntravenous Ibuprofen
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.8
PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.

The incidence of treatment-emergent adverse events occurring in the six hours following administration of the first dose of intravenous ibuprofen

Time frame:
6 hours
Reported as:
Number · Number of Adverse Events
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.
Number of Adverse EventsIntravenous Ibuprofen
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.49
SecondaryTo Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.

The incidence of treatment-emergent serious adverse events occurring in the six hours following administration of the last dose of intravenous ibuprofen

Time frame:
6 hours
Reported as:
Number · Number of Serious Adverse Events
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.
Number of Serious Adverse EventsIntravenous Ibuprofen
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.0
SecondaryTo Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.

The incidence of treatment-emergent adverse events occurring in the six hours following administration of the last dose of intravenous ibuprofen

Time frame:
6 hours
Reported as:
Number · Number of Adverse Events
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.
Number of Adverse EventsIntravenous Ibuprofen
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.16
SecondaryTo Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.

Visual Analog Scale (VAS) assessments following surgery. The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between o and 100.

Time frame:
6 hours
Reported as:
Mean · units on a scale
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.
units on a scaleIntravenous Ibuprofen
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.30.9 (27.5 to 34.2)

Adverse events

Collected over During and after dosing with intravenous ibuprofen until 6 hours following the last dose of intravenous ibuprofen. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous Ibuprofen—8/300 (2.7%)49/300 (16.3%)
Most frequent serious events
Most frequent serious events
EventIntravenous Ibuprofen
Abdominal Compartment SyndromeGastrointestinal disorders1/300
Peritoneal AdhesionsGastrointestinal disorders1/300
Bile Duct StoneHepatobiliary disorders1/300
Airway Complication Of AnaesthesiaInjury, poisoning and procedural complications1/300
Oxygen Saturation DecreasedInvestigations1/300
PneumothoraxRespiratory, thoracic and mediastinal disorders1/300
HypertensionVascular disorders1/300
Urinary RetentionRenal and urinary disorders1/300
Most frequent other events
Most frequent other events
EventIntravenous Ibuprofen
Infusion Site PainGeneral disorders34/300
NauseaGastrointestinal disorders10/300
Anaemia PostoperativeInjury, poisoning and procedural complications10/300
FlatulenceGastrointestinal disorders9/300
BradycardiaCardiac disorders8/300

Baseline characteristics

Formal sample size calculations were not performed. The intent is to enroll 300 patients to provide descriptive safety and efficacy data.

Age, Customized
Age, Customized(years)Intravenous Ibuprofen
Greater than or equal to 18 years of age300
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous Ibuprofen
Female189
Male111
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intravenous Ibuprofen
Hispanic or Latino29
Not Hispanic or Latino271
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intravenous Ibuprofen
American Indian or Alaska Native1
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American60
White229
More than one race0
Unknown or Not Reported5
Region of Enrollment
Region of Enrollment(participants)Intravenous Ibuprofen
United States300
08

Study locations

22 sites
  • UC San Diego Regional Center
    La Jolla, California 92037, United States
  • Neurovations (Queen of the Valley Hospital)
    Napa, California 94558, United States
  • University of Miami Health System
    Miami, Florida 33136, United States
  • Sheridan Clinical Research
    Plantation, Florida 33324, United States
  • RUSH Univ. Medical Center
    Chicago, Illinois 60612, United States
  • Univ. of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121-2483, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Detroit Medical Center
    Detroit, Michigan 48201, United States
  • North Mississippi Sports Medicine & Orthopaedic Clinic
    Tupelo, Mississippi 38801, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • State of New York Downstate Medical Center (SUNY)
    Brooklyn, New York 11203, United States
  • North Shore - Long Island Jewish Health System
    Manhasset, New York 11030, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43201, United States
  • Penn State College of Medicine
    Hershey, Pennsylvania 17033, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Hendersonville Hospital/Comprehensive Pain Specialists
    Hendersonville, Tennessee 37075, United States
  • Parkland Memorial
    Dallas, Texas 75235, United States
09

References and documents

Publications

  • Gan TJ, Candiotti K, Turan A, Buvanendran A, Philip BK, Viscusi ER, Soghomonyan S, Bergese SD; Intravenous Ibuprofen Surgical Surveillance Trial Investigational Sites. The shortened infusion time of intravenous ibuprofen, part 2: a multicenter, open-label, surgical surveillance trial to evaluate safety. Clin Ther. 2015 Feb 1;37(2):368-75. doi: 10.1016/j.clinthera.2014.12.006. Epub 2015 Jan 13. PubMed 25592331 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Dec 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2011
First posted
Apr 13, 2011
Start
Jun 2011
Primary completionActual
Dec 2012
CompletionActual
Jan 2013
Results first posted
Jun 23, 2014
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01334957
Responsible party
Sponsor
First posted
Apr 13, 2011
Start date
Jun 2011
Primary completion
Dec 2012
Completion
Jan 2013
Results posted
Jun 23, 2014
Last update
Feb 28, 2024

Study contacts

Art P Wheeler, M.D.
study director · Cumberland Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion